Therefore, tezepelumab can be a suitable agent for the treatment of ABPA, since it binds to and inhibits TSLP, an epithelial cell–derived proinflammatory cytokine implicated in multiple downstream processes including IL‐5, IL‐13 and ILC2 pathways. The gene discussed is IL5; the disease is allergic bronchopulmonary aspergillosis.